KRAS抑制剂开发历程引人注目，充满激情与煎熬。从1982年发现KRAS激活突变到2013实现关键结构研究突破，整整40年的时间都被认为是“不可成药”靶点。而从2013年到如今几十款药物走出实验室，仅仅用了10年的时间。而KRAS抑制剂耐药的发生比预 ...

Initial results from randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care in RAS-mut mCRC demonstrated ...

Cardiff Oncology plans to share additional clinical data from its onvansertib trial in the first half of 2025.

文章中，研究人员发现，突变的 RAS 有助于启动一系列涉及特定核蛋白运输的事件，从而导致失控的肿瘤生长。RAS基因是癌症中第二大常见的突变基因，而突变的RAS蛋白也是其中一些最致命癌症的关键驱动因素，包括几乎所有的 胰腺癌 ，一半 结直肠癌 ...

Cardiff Oncology CRDF announced robust efficacy data from an ongoing mid-stage study evaluating two doses of its lead ...

他们发现，突变的RAS协助启动了一系列涉及特定核蛋白运输的事件，进而导致肿瘤不受控制地生长。这项成果于2024年11月11日发表在《Nature Cancer》杂志上。 RAS基因是癌症中经常突变的基因之一，突变的RAS蛋白是一些致命癌症的关键驱动因素，包括几乎所有的胰腺 ...

US biotech Cardiff Oncology has announced positive initial data from CRDF-004, a randomized, Phase II trial evaluating ...

An update from Cardiff Oncology ( (CRDF) ) is now available. Cardiff Oncology has reported promising initial results from its ...

Cardiff Oncology’s investigational PLK1 inhibitor paired with standard-of-care treatment showed a 64% overall response rate ...

(RTTNews) - w Inc. (CRDF), a clinical-stage biotechnology company, on Tuesday said it has priced its underwritten offering of about 15.385 ...

Cardiff Oncology's stock rose Monday morning after it announced positive initial data from a trial of its experimental drug onvansertib for treating a type of colon cancer. The stock was up 45% at ...